HOME
ABOUT IAC
CONTACT
A-Z INDEX
DONATE
SHOP
SUBSCRIBE
Immunize.org logo formerly Immunization Action Coalition (IAC)
IAC Home
|
News & Information
|
Official Releases

Official Releases

View All 2022

JAN
spacer
FEB
spacer
MAR
spacer
APR
spacer
MAY
spacer
JUN
spacer
JUL
spacer
AUG
spacer
SEP
spacer
OCT
spacer
NOV
spacer
DEC
#
December 2022 Back to top
CDC expands updated COVID-19 vaccines to include children ages 6 months through 5 years 
CDC - 12/9/22
 
FDA authorizes updated (bivalent) COVID-19 vaccines for children down to 6 months of age
FDA Approval - 12/8/22
 
#
November 2022 Back to top
ACIP recommends Priorix (GSK) as an additional option to prevent MMR according to existing vaccine recommendations and off-label uses, US, 2022 
ACIP Recommendations - 11/18/22
 
Updated Vaccine Information Statement (VIS) for smallpox/monkeypox vaccine (Jynneos) released 
CDC - 11/14/22
 
ACIP interim recommendations for the use of bivalent booster doses of COVID-19 vaccines, US October 2022
ACIP Recommendations - 11/11/22
 
#
October 2022 Back to top
CDC allows those 18 years and older option to receive a Novavax monovalent booster instead of an updated (bivalent) Pfizer-BioNTech or Moderna booster if they have completed primary series vaccination but have not previously received a COVID-19 booster.
CDC - 10/19/22
 
FDA issues EUA for Novavax COVID-19 Vaccine to provide a first booster dose to individuals 18 years of age and older for whom an FDA-authorized mRNA bivalent COVID-19 booster vaccine is not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Novavax COVID-19 Vaccine
FDA Approval - 10/19/22
 
FDA approves a one vial presentation (no reconstitution) of Menveo (GSK) for use in individuals 10 through 55 years of age
FDA Approval - 10/14/22
 
CDC recommends expanding the use of updated (bivalent) COVID-19 vaccines (Pfizer-BioNTech for children ages 5 through 11 years, Moderna for children and adolescents ages 6 through 11 years) to children ages 5 through 11 years. 
CDC - 10/12/22
 
FDA amends EUAs to authorize bivalent formulations of the vaccine (Pfizer-BioNTech for children ages 5 through 11 years, Moderna for children and adolescents ages 6 through 17 years) for use as a single booster dose two months after a primary series or booster dose. 
FDA Approval - 10/12/22
 
FDA approves Boostrix (GSK) as first vaccine specifically for use during third trimester pregnancy to prevent whooping cough in infants younger than two months of age.  Boostrix is already indicated for booster immunization against tetanus, diphtheria, and pertussis in those 10 years and over and previously been approved for use in pregnancy to protect the mother.
FDA Approval - 10/7/22
 
#
September 2022 Back to top
ACIP recommendation for the use of cholera (Vaxchora, Emergent Biosolutions) vaccine
ACIP Recommendations - 9/30/22
 
ACIP recommends use of PCV15 as an option for pneumococcal vaccination for children under 19 years of age, using currently recommended PCV13 dosing and schedules 
ACIP Recommendations - 9/16/22
 
US joins list of 30 countries that meet WHO criteria for circulating vaccine-derived poliovirus (cVDPV) 
CDC - 9/13/22
 
CDC recommends the first updated COVID-19 booster (bivalent booster) 
CDC - 9/1/22
 
#
August 2022 Back to top
FDA amended EUAs of Moderna COVID-19 vaccine and Pfizer-BioNTech COVID-19 vaccine to authorize bivalent formulations of the vaccines for use as a single booster dose at least two months following primary or booster vaccination (monovalent COVID-19 vaccines are not authorized as booster doses for individuals 12 years of age and older)
FDA Approval - 8/31/22
 
Prevention and Control of Seasonal Influenza with Vaccines, 2022-23
ACIP Recommendations - 8/26/22
 
Updated Vaccine Information Statement (VIS) for smallpox/monkeypox vaccine (Jynneos) released
CDC - 8/23/22
 
CDC recommends Novavax COVID-19 vaccine for use in adolescents 12 years through 17 years as a primary series option.
CDC - 8/22/22
 
FDA expands age indication of Novavax COVID-19 vaccine, adjuvanted EUA to include use in individuals 12 years of age and older
FDA Approval - 8/19/22
 
FDA issues EUA of JYNNEOS (Bavarian Nordic A/S) vaccine allowing subcutaneous administration to under 18 years of age and intradermal administration of vaccine to 18 years and older to increase vaccine supply 
FDA Approval - 8/9/22
 
ACIP interim recommendation for use of Novavax COVID-19 vaccine in adults 18 years and older, US, July 2022
ACIP - 8/5/22
 
#
July 2022 Back to top
FDA issues EUA for Novavax (Novavax, Inc), COVID-19 vaccine adjuvanted to provide a two-dose primary series to individuals 18 years of age and older 
FDA Approval - 7/13/22
 
FDA expands age indication of Comirnaty (Pfizer-BioNTech) vaccine to include use in adolescents 12 years through 15 years of age for a two dose primary series.  The EUA remains in effect for additional doses for immunocompromised for 12 years of age and older and for booster doses 
FDA Approval - 7/8/22
 
#
June 2022 Back to top
New Vaccine Information Statement (VIS) posted for Ebola vaccine
CDC - 6/30/22
 
ACIP interim recommendations for use of Moderna and Pfizer-BioNTech COVID-19 vaccines in children aged 6 Months–5 Years — US, June 2022 
ACIP - 6/28/22
 
CDC endorsed ACIP recommendation of Moderna’s COVID-19 vaccine for those 6 through 17 years of age, in addition to its already recommended use in children 6 months through 5 years and adults 18 years and older 
CDC – 6/24/22
 
CDC endorsed the ACIP recommendation that all children 6 months through 5 years of age should receive a Moderna or Pfizer-BioNTech COVID-19 vaccine.  All children, including children who have already had COVID-19, should get vaccinated
CDC – 6/18/22
 
FDA amends Moderna COVID-19 EUA to include use of the vaccine in individuals 6 months through 17 years of age. The vaccine had been authorized for use in adults 18 years of age and older
FDA Approval - 6/17/22
 
FDA amends Pfizer-BioNTech COVID-19 EUA to include use of the vaccine in individuals 6 months through 4 years of age. The vaccine had been authorized for use in individuals 5 years of age and older 
FDA Approval - 6/17/22
 
FDA approves expanded age recommendation for Vaxneuvance (PCV15, Merck) to individuals 6 weeks and older 
FDA Approval - 6/17/22
 
FDA approves Priorix (GSK) (Measles, Mumps and Rubella Vaccine, Live) vaccine for the prevention of measles, mumps and rubella in individuals 12 months of age and older
FDA Approval - 6/3/22
 
Updated Vaccine Information Statement (VIS) for rabies vaccine released
CDC – 6/2/22
 
New Vaccine Information Statement (VIS) for smallpox/monkeypox vaccine (Jynneos) released 
CDC - 6/1/22
 
#
May 2022 Back to top
ACIP recommendations for use of Jynneos (smallpox and monkeypox vaccine, live, nonreplicating) for preexposure vaccination of persons at risk for occupational exposure to orthopoxviruses, US, 2022 
ACIP Recommendations - 5/27/22
 
CDC recommends that children ages 5 through 11 years should receive a booster shot 5 months after their initial Pfizer-BioNTech vaccination series, strengthens its recommendation that those 12 and older who are immunocompromised and those 50 and older should receive a second booster dose at least 4 months after their first 
CDC – 5/19/22
 
FDA amends EUA and expands eligibility for Pfizer-BioNTech COVID-19 vaccine booster dose to children 5 through 11 Years 
FDA Approval - 5/17/22
 
ACIP updates rabies vaccine recommendations - Use of a modified preexposure prophylaxis vaccination schedule to prevent human rabies, US, 2022 
ACIP Recommendations - 5/6/22
 
FDA limits use of Janssen (J&J) vaccine to certain individuals-Fact sheet for Healthcare Providers and Recipients and Caregivers revised 
FDA Approval - 5/5/22
 
#
April 2022 Back to top
ACIP recommends universal hepatitis B vaccination in adults aged 19-59 Years, US, 2022
ACIP Recommendations – 4/1/22
 
#
March 2022 Back to top
CDC recommends additional boosters for certain Individuals
CDC – 3/29/22
 
FDA amends EUA, authorizes an additional presentation of Moderna COVID-19 vaccine for booster vaccination doses, not authorized for primary series doses (dark blue caps with purple border labels)
FDA Approval - 3/29/22
 
FDA authorizes second booster dose of Pfizer-BioNTech or the Moderna COVID-19 vaccines for older and immunocompromised individuals
FDA Approval - 3/29/22
 
ACIP Recommendation for use of Moderna COVID-19 Vaccine in Adults aged 18 years and older, considerations for extended intervals for primary series doses of mRNA COVID-19 vaccines — US, February 2022 
ACIP Recommendations - 3/18/22
 
#
February 2022 Back to top
Use of Ebola Vaccine: Expansion of ACIP Recommendations to include two additional populations, US, 2021.
ACIP Recommendations - 2/25/22
 
2022 U.S. Recommended Immunization Schedule for Adults Aged 19 Years or Older
CDC - 2/18/22
 
2022 U.S. Recommended Immunization Schedules for Children and Adolescents Aged 18 Years or Younger
CDC - 2/18/22
 
CDC's latest information about Vaccine Information Statements (VIS) currently under development or newly released.
CDC – 2/4/22
 
New Vaccine Information Statement (VIS) for pneumococcal conjugate vaccine (PCV13, PCV15, and PCV20) released.
CDC – 2/4/22
 
Updated VIS for recombinant zoster (shingles) vaccine released.
CDC – 2/4/22
 
#
January 2022 Back to top
FDA approves COVID-19 vaccine Spikevax (Moderna) as a two dose primary series for individuals 18 years and older. The EUA remains in effect for third primary series dose and booster dose.
FDA Approval – 1/31/22
 
ACIP updates recommendations for adults on use of 15-Valent Pneumococcal Conjugate Vaccine (Vaxneuvance, Merck) PCV15 and 20-Valent Pneumococcal Conjugate Vaccine (Prevnar 20, Pfizer), US, 2022.
ACIP Recommendations - 1/28/22
 
ACIP Recommendations for Use of Recombinant Zoster Vaccine (RZV, Shingrix, GSK) in Immunocompromised Adults aged 19 years and older, US, 2022.
ACIP Recommendations – 1/21/22
 
ACIP Updated Interim Recommendations for Use of the Janssen (Johnson & Johnson) COVID-19 vaccine, US, December 2021.
ACIP Recommendations - 1/21/22
 
FDA shortens interval to booster dose of Moderna COVID-19 vaccine to 5 months.
FDA Approval - 1/7/22
 
CDC endorses ACIP recommendation to expand eligibility of booster doses to those 12 to 15 years old. CDC recommends that all adolescents age 12 to 17 years old should receive a booster shot 5 months after their initial Pfizer-BioNTech vaccination series.
CDC - 1/5/22
 
CDC recommends Pfizer-BioNTech booster 5 months after completing primary series. CDC recommends moderately or severely immunocompromised 5–11-year-olds receive an additional primary dose of Pfizer-BioNTech COVID-19 vaccine 28 days after their second shot.
CDC - 1/4/22
 
FDA amends EUA Pfizer-BioNTech vaccine - expands use of a single booster dose to include 12 through 15 years of age, shortens time to booster dose to at least 5 months, and allows for third primary dose for certain immunocompromised children 5 through 11 years of age.
FDA Approval - 1/3/22
 
Official Releases
- ACIP: Advisory Committee on Immunization Practices
- CDC: Centers for Disease Control and Prevention
- FDA: Food and Drug Administration
View All Recent Official Releases
Archives of Official Releases
- 2021 Archive
- 2020 Archive
- 2019 Archive
- 2018 Archive
- 2017 Archive
- 2016 Archive
- 2015 Archive
News & Information Home
Additional Information
Vaccine Policy & Licensure
One-stop shop for official information about vaccines
State Immunization Information
Health department websites and managers, and laws
           
 
VIEW ALL:
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
2015
 
             
 
This page was updated on December 9, 2022.
This page was reviewed on December 9, 2022.
 
             
 
- Guide to immunize.org -
A-Z INDEX
ABOUT IAC
IAC in the News
Staff
IAC History through Film
ACIP
RECOMMENDATIONS
ADOLESCENT VACCINATION
ADULT VACCINATION
ADULT VACCINATION GUIDE
ASK THE EXPERTS
Administering Vaccines
COVID-19
Hepatitis B
MMR
Storage and Handling
>> view all
BECKY PAYNE AWARD
BILLING & CODING
BIRTH DOSE GUIDEBOOK
CALENDAR OF EVENTS
CDC INFORMATION
CDC SCHEDULES
CLINIC TOOLS
Administering Vaccines
Adolescent Vaccination
Adult Vaccination
Screening for Contraindications
Storage & Handling
Vaccine Recommendations
>> view all
COALITIONS FOR
IMMUNIZATION
CONTRIBUTE TO IAC
COVID-19 RELATED
Ask the Experts: COVID-19
Vaccines: COVID-19
DEAR COLLEAGUE LETTERS
16-year-old Visit
HPV
MenACWY Dose #2
DONATE TO IAC
EDUCATIONAL MATERIALS
EMAIL NEWS SERVICES
E-NEWSLETTER: IZ EXPRESS
EXEMPTIONS
FAQs
FAVORITES
FDA PACKAGE INSERTS
FILMS ABOUT IAC
GIVE BIRTH TO THE
END OF HEP B
HANDOUTS FOR
PATIENTS & STAFF
View All Materials
Administering Vaccines
Adolescent Vaccination
Adult Vaccination
Contraindications / Precautions
Documenting Vaccination
Healthcare Personnel
Managing Vaccine Reactions
Parent Handouts
Pregnancy and Vaccines
Q&As: Diseases and Vaccines
Schedules for Patients
Screening Checklists
Standing Orders Templates
Storage & Handling
Strategies & Policies
Temperature Logs
Top Handouts
Vaccine Confidence
Vaccine Recommendations
>> view all
HEP B BIRTH DOSE
HONOR ROLLS
Hep B Birth Dose
Mandatory Flu Vaccination for HCP
MenB Vaccination for Colleges
IZ EXPRESS
Subscribe to IZ Express
IMAGE LIBRARY
LAWS AND MANDATES
MANUFACTURERS
MASS VACCINATION
RESOURCES
NATIONAL ADULT &
INFLUENZA
IMMUNIZATION SUMMIT
NEWS & INFORMATION
NEWSLETTER SIGN UP
OFFICIAL RELEASES
ACIP
CDC
FDA
PACKAGE INSERTS
PARTNERS
PHARMACISTS
PHOTOS
PREGNANCY AND
VACCINES
PRESS ROOM
PROTECT NEWBORNS
FROM HEP B
PUBLICATIONS
IZ Express
Vaccinating Adults:
   A Step-by-Step Guide
Hepatitis B What Hospitals
   Need to Do to
   Protect Newborns
Needle Tips Archive
Vaccinate Adults Archive
Vaccinate Women Archive
REGISTRIES
SCHOOL VACCINATION REQUIREMENTS
SHOP IAC
DVD Immunization Techniques
Laminated Schedules
Patient Record Cards
Flu Vaccine Buttons and Stickers
"Vaccines Save Lives" Pins
SITE MAP
STANDING ORDERS
STATE INFORMATION
Immunization Websites
Laws and Mandates for School Entry
Immunization Program Managers
SUBSCRIBE TO IZ EXPRESS
SUPPORT IAC
TALKING ABOUT VACCINES
Adjuvants & Ingredients
Autism
Importance of Vaccination
MMR Vaccine
Religious Concerns
Vaccine Safety
>> view all
TECHNICALLY SPEAKING
(ARCHIVE)
TRANSLATIONS
IAC Handouts
VISs
TRAVEL (INTERNATIONAL)
UNPROTECTED PEOPLE
STORIES
Chickenpox
Hepatitis B
Measles
Whooping Cough
>> view all
VACCINATING ADULTS:
A STEP-BY-STEP GUIDE
VACCINE INFORMATION
STATEMENTS
Translations
VACCINE
MANUFACTURERS
VACCINE POLICY &
LICENSURE
ACIP
FDA
WHO
VACCINE SAFETY
VACCINE TIMELINE
VACCINES
COVID-19
Hepatitis B
HPV (Human papillomavirus)
Influenza
Monkeypox (mpox)
Pertussis
Varicella
>> view all
VIDEO OF THE WEEK
VIDEO LIBRARY
VISs
Translations
WHAT'S NEW OR UPDATED AT IAC
Handouts
VISs and Translations
Web Pages
 
Immunize.org  •  2136 Ford Parkway  •  Suite 5011  •  Saint Paul, Minnesota  •  55116
tel 651-647-9009  •  fax 651-647-9131
 
 
 
This website is supported in part by a cooperative agreement from the National Center for Immunization and Respiratory Diseases (Grant No. 1NH23IP922654) at the Centers for Disease Control and Prevention (CDC) in Atlanta, GA. The website content is the sole responsibility of IAC and does not necessarily represent the official views of CDC.